Comparison · NCT05296629-d240405a
DFD-29 vs Placebo: Clinician's Erythema Assessment (CEA) Compared to Placebo.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DFD-29 vs Placebo: Clinician's Erythema Assessment (CEA) Compared to Placebo. Trial comparisons, record NCT05296629-d240405a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05296629-d240405a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.32 | 0.244 | 0.407 | wilson | |
| Risk in group 2 | 0.138 | 0.0785 | 0.23 | wilson | |
| Risk difference, group 1 minus group 2 | 0.182 | 0.0626 | 0.287 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.32 | 1.27 | 4.27 | log | |
| Odds ratio, group 1 over group 2 | 2.95 | 1.4 | 6.19 | log | |
| Number needed to treat, for one more participant with the outcome on DFD-29 than on Placebo | 5.49 | 3.48 | 16 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DFD-29 | DFD-29 (40 mg) extended release capsules~DFD-29: DFD-29 (40 mg) extended release capsules | 39 | 122 | OG000 |
| Group 2 | Placebo | Placebo capsules matching DFD-29~Placebo: Placebo capsules | 11 | 80 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Clinician's Erythema Assessment (CEA) Compared to Placebo.
- Description
- Proportion of subjects with at least 2-grade reduction in CEA score from Baseline to Week 16 in the DFD-29 group compared to Placebo.
- Time frame
- Baseline to Week 16.
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- NCT number
- NCT05296629
- Phases
- PHASE3
- Conditions
- Papulopustular Rosacea
- Interventions
- DFD-29, Doxycycline, Placebo
- Lead sponsor
- Journey Medical Corporation
- Results first posted
- 2024-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05296629?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05296629-d240405a